NERV · Minerva Neurosciences, Inc.

Track NERV — free

$3.32 +0.04 (+1.22%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$162.34M

47.75M

Volume · Oct 5 72.36K Avg daily vol (3M) 189.33K

Up next

Latest filing: 10-Q

filed Aug 7, 2026

Q1 2023 earnings call transcript

call held May 15, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$394.35M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+945.1%

Year over year · more shares

Price change (1Y)

+55.7%

Trailing year

Short interest

5.1%

Latest settlement · 20.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −35%

below

Price vs 50-day avg −21%

below

RSI (14) 33

neutral

MACD trend Negative

52-week position 20%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −30%

trailing

6-month return −42%

trailing

YTD return −18%

this year

Relative strength −55%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $4 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+30% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.07% of float · ▲ +14.6% MoM · 20.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

61 holders — near 3-yr high, broad support

Squeeze score 70

high risk · 0–100

Fundamentals

Poor

EPS growth −18347%

Y/Y

Free cash flow $-13.5M

Quant / Vol

risk profile

Very High

Volatility 172%

annualized · 1-yr

Max drawdown −60%

past year

ATR 8.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−35% Bearish

Price vs 50-day avg

−21% Bearish

RSI (14)

33 Neutral

MACD trend

Negative Bearish

52-week position

20% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $4 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+30% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.07% of float · ▲ +14.6% MoM · 20.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

61 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $3 · 20% Range high $8

vs 200-day avg -35% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Total liabilities - non-GAAP non-GAAP	3.96M	June 30, 2026	—
GAAP → non-GAAP reconciliation GAAP Total liabilities - GAAP 296.65M -232.69M Warrant liability -60M Liability related to the sale of future royalties = Total liabilities - non-GAAP 3.96M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NERV Minerva Neurosciences, Inc. this stock	$162.34M	-18.4%	—	—	5.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 88.6%
Net QoQ: +4.0M sh
Top holder: FEDERATED HERMES, INC.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

2.4M

Days to cover: 20.1d
Change: +309.0K sh

View

Short Volume

Short vol %

72%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

4.3K

Value: $18.0K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

37.5%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-293.4M
EPS diluted: $-34.67

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 14

View

Proposed Sales

Value

$70.4K

Shares: 8.8K
Filed: Mar 31, 2026

View

Exempt Offerings

Offering

$20.0M

Filed: Jul 3, 2023

View

Earnings & Events

Webcasts

Last webcast

Jun 4, 2026

View

Performance

	5D	20D	120D	MTD	YTD
NERV	-3.5%	-30.1%	-42.5%	-2.1%	-18.4%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-3.3%	-29.6%	-54.6%	-3.0%	-31.3%

Key facts CIK 1598646 CUSIP 603380205 13F (30d) 2 filings 2 filers Visit website Investor relations

NERV · Minerva Neurosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance